Perrigo boss on the largest tax bill ever issued by Revenue
Business interview: CEO Murray Kessler talks Covid and sorting out Perrigo’s Irish tax bill
Perrigo sells Tysabri rights to Royalty Pharma in €2.7bn deal
Dublin-domiciled group finally gets hold of MS drug revenue it initially pursed from Elan in 2013
Royalty Pharma drops hostile bid for Elan
US-based investor withdraws request for judicial review of Takeover Panel’s decision requiring it to lapse Elan offer
Elan loses shareholder support but Royalty bid may also perish
Outcome of special meeting in Dublin leaves sides effectively in stalemate
Stalemate for Royalty Pharma’s bid for Elan as shareholders approve buyback programme
US pharma firm invited to bring forward “a new offer” following egm
Royalty Pharma co-founder writes open letter to board of Elan ahead of egm
Elan shareholders will today vote on a series of acquisitions
INM EGM to vote on proposed disposal of South African assets
Elan shareholders to vote on transactions
Elan shareholders mull the unravelling of a business
How the Irish biotech firm got to this point and how the EGM may play out
Elan puts itself on market as prospects for restructuring plan fade
Review of proxies suggests stalemate after four-month battle for control of company
Elan puts itself up for sale
Irish drug company seeking to fend off a hostile bid by US pharmaceutical investor Royalty Pharma
Elan shares rise as investors vote against transactions
Majority of investors voted against proposals that stand in way of Royalty Pharma’s $6.7 billion bid
Royalty gets injunction in challenge to Takeover Panel on Elan bid
Court move means bid will not lapse pending full hearing even if shareholders back certain resolutions
Royalty bid for Irish drugmaker Elan in trouble
US pharmaceutical investor says it does not appear to have backing of Elan shareholders
Failure of Royalty Pharma bid likely to hit Elan share price, say analysts
Fate of $6.7bn offer will be decided by shareholders at extraordinary general meeting on Monday
Much noise, little clarity as Royalty and Elan go to war
Cantillon: Shareholders at Elan must be nonplussed by the frantic claim and counterclaim
Royalty looks to fast-track challenge to Takeover Panel ruling
Fund seeks stay on decision regarding $6.7bn Elan bid until Commercial Court rules
Elan bid defence under attack from former director
Elan dismisses claims by Jack Schuler whom it calls ‘disgruntled’ as Royalty challenges Takeover Panel ruling
Royalty Pharma challenges ruling that it must withdraw Elan bid
Deadline looms for vote of proxies in bitter battle
Elan battle intensifies as Royalty Pharma raises offer by 5 per cent
Tysabri manufacturer’s shares rise 5.3 per cent
Royalty raises Elan bid to potential $8bn
Move comes after 7.5% of shareholders in Irish drugs firm supported previous offer
Elan’s behaviour is “deplorable”
Bidder Royalty Pharma argues that pharmaceutical firm’s law suits are “without merit”
Elan drops Royalty Pharma injunction as Takeover Panel steps in
Bid target says suitor agrees to hold back on proxy statement to shareholders
Elan formally rejects enhanced Royalty Pharma offer
Elan continues to insist the offer “substantially undervalues” the value of Tysabri
Royalty cuts acceptance bar for Elan bid to 50%
US firm has raised hostile cash bid for Dublin-based drug maker to $12.50 per share
Elan urges shareholders to reject Royalty Pharma offer
Company says bid fails to properly value business
Elan claims success in battle with Royalty after $11.25 a share buyback
Analysts say reluctance of investors to tender stock a poor sign for drug firm’s suitor
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Election 2024
Full general election coverage including analysis and results for all 43 constituencies
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices